<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Salmeterol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Salmeterol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Salmeterol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9875" href="/d/html/9875.html" rel="external">see "Salmeterol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11857" href="/d/html/11857.html" rel="external">see "Salmeterol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709408"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Asthma-related death:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-acting beta-2 adrenergic agonists (LABAs), such as salmeterol, as monotherapy (without inhaled corticosteroids) increase the risk of asthma-related death. Data from a large, placebo-controlled, US study that compared the safety of salmeterol or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13,176 patients treated for 28 weeks on salmeterol versus 3 deaths out of 13,179 patients on placebo). Use of background inhaled corticosteroids (ICS) was not required in this study. When LABAs are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone.</p>
<p style="text-indent:-2em;margin-left:2em;">Use of salmeterol for the treatment of asthma as monotherapy without a concomitant ICS is contraindicated. Use salmeterol only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ICS. Do not use salmeterol for patients whose asthma is adequately controlled on low- or medium-dose ICS.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric and adolescent patients:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Available data from controlled clinical trials suggest that LABAs as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent patients. For pediatric and adolescent patients with asthma who require addition of a LABA to an ICS, a fixed-dose combination product containing both an ICS and a LABA should ordinarily be used to ensure adherence with both drugs. In cases where use of an ICS and a LABA is clinically indicated, appropriate steps must be taken to ensure adherence with both treatment components. If adherence cannot be ensured, a fixed-dose combination product containing both an ICS and a LABA is recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F219869"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Serevent Diskus</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868210"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Serevent Diskus</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1061999"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenergic Agonist Agent</span>;</li>
<li>
<span class="list-set-name">Antiasthmatic</span>;</li>
<li>
<span class="list-set-name">Beta<sub>2</sub>-Adrenergic Agonist</span>;</li>
<li>
<span class="list-set-name">Bronchodilator</span></li></ul></div>
<div class="block dop drugH1Div" id="F219893"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c809d59-12de-4789-a830-b048cd9fbce6">Asthma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma: Note:</b> Not indicated for relief of acute bronchospasm. For asthma treatment, long-acting beta<sub>2</sub>-agonists (LABAs), such as salmeterol should always be used in combination with inhaled corticosteroids (ICS); use without ICS is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents: Dry powder inhaler: 50 mcg/inhalation: Oral inhalation: One inhalation twice daily, ~12 hours apart.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea840e89-1dfd-4a61-bfa4-2dc7da759a32">Exercise-induced bronchospasm, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exercise-induced bronchospasm, prevention:</b>
<b>Note:</b> Because LABAs may disguise poorly controlled persistent asthma, frequent or chronic use of LABAs for exercise-induced bronchospasm is discouraged by asthma guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>). Tolerance to the protective effects of LABAs against exercise-induced bronchospasm may develop with greater than once-daily use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27665489','lexi-content-ref-23634861','lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents: Dry powder inhaler: 50 mcg/inhalation: Oral inhalation: One inhalation at least 30 minutes prior to exercise; additional doses should not be used for 12 hours; should not be used in individuals already receiving salmeterol twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192783"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51192784"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, salmeterol is primarily cleared in the liver and plasma levels may be increased. Use with caution and monitor closely.</p></div>
<div class="block doa drugH1Div" id="F219874"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9875" href="/d/html/9875.html" rel="external">see "Salmeterol: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Do not use for the relief of acute bronchospasm.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6caa2026-eddb-48a2-b18b-6f34544a7019">Asthma/Bronchospasm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma/Bronchospasm:</b> Dry powder inhaler (50 mcg/actuation): <b>Oral inhalation:</b> One inhalation twice daily (~12 hours apart); maximum: 1 inhalation twice daily. <b>Note:</b> For asthma control, long-acting beta-2 agonists (LABAs) should be used in combination with inhaled corticosteroids and not as monotherapy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c6f4720-28f3-4c2d-84c9-7afdfa8fd1a7">Chronic obstructive pulmonary disease, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic</b>
<b>obstructive pulmonary disease, maintenance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Depending on symptoms and exacerbation risk, use in combination with long-acting bronchodilators (long-acting beta agonist and long-acting muscarinic antagonist). In addition, a short-acting bronchodilator is used for symptom relief (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dry powder inhaler (50 mcg/actuation): <b>Oral inhalation: </b>One inhalation twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95c32f3a-f16a-445e-b218-18e8d3ce3500">Exercise-induced bronchospasm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exercise-induced bronchospasm: Note:</b> Alternatively, may consider a combination ICS-formoterol (preferred) for either an as-needed basis or for maintenance of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Dry powder inhaler (50 mcg/actuation): <b>Oral inhalation:</b> One inhalation at least 30 minutes prior to exercise; additional doses should not be used for 12 hours or used in individuals already receiving salmeterol twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990922"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988208"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, salmeterol is primarily cleared in the liver and plasma levels may be increased. Use with caution and monitor closely.</p></div>
<div class="block adr drugH1Div" id="F219841"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Central nervous system: Headache (13% to 17%), pain (1% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (4%), edema (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (4%), sleep disorder (1% to 3%), anxiety (1% to 3%), migraine (1% to 3%), paresthesia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1% to 4%), contact dermatitis (1% to 3%), eczema (1% to 3%), urticaria (3%), photodermatitis (1% to 2%), pallor</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (1% to 3%), gastrointestinal infection (1% to 3%), nausea (1% to 3%), oropharyngeal candidiasis (1% to 3%), toothache (1% to 3%), xerostomia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (≤3%), muscle spasm (≤3%), arthritis (1% to 3%), arthralgia (1% to 3%), muscle rigidity (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (≤3%), keratitis (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion (4% to 9%), bronchitis (≤7%), throat irritation (7%), tracheitis (≤7%; may be paradoxical), pharyngitis (≤6%), cough (5%), viral respiratory tract infection (5%), sinusitis (4% to 5%), rhinitis (4% to 5%), asthma (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, agitation, aggressive behavior, anaphylaxis (some in patients with severe milk allergy), angioedema, aphonia, atrial fibrillation, bruise, cardiac arrhythmia, cataract, chest congestion, chest tightness, choking sensation, eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss), Cushing's syndrome, Cushingoid appearance, decreased linear skeletal growth rate (children and adolescents), depression, dysmenorrhea, dyspnea, ecchymoses, edema (facial, oropharyngeal), eosinophilia, glaucoma, hypercorticoidism, hypersensitivity reaction (immediate and delayed), hypokalemia, hypothyroidism, increased intraocular pressure, irregular menses, laryngospasm, local irritation (larynx), myositis, oropharyngeal irritation, osteoporosis, otalgia, paradoxical bronchospasm, pelvic inflammatory disease, prolonged QT interval on ECG, restlessness, sinus pain (paranasal), stridor, supraventricular tachycardia, syncope, tremor, vaginitis, vulvovaginal candidiasis, vulvovaginitis, ventricular tachycardia, weight gain</p></div>
<div class="block coi drugH1Div" id="F219856"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to salmeterol or any component of the formulation; severe hypersensitivity to milk proteins; monotherapy in the treatment of asthma (ie, use without concomitant inhaled corticosteroid); treatment of status asthmaticus or other acute episodes of asthma or COPD</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Presence of tachyarrhythmias</p></div>
<div class="block war drugH1Div" id="F219838"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma-related deaths: <b>[US Boxed Warning]: Monotherapy with a long-acting beta-2 agonist (LABA) is contraindicated in the treatment of asthma. LABAs as monotherapy (without inhaled corticosteroids) increase the risk of asthma-related death. Data from a large, placebo-controlled clinical trial demonstrated an increase in asthma-related deaths in patients treated with salmeterol (when added to usual asthma therapy); use of background inhaled corticosteroids was not required. When LABAs are used in a fixed-dose combination with inhaled corticosteroids, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to inhaled corticosteroids alone. Salmeterol should only be used in asthma patients as adjuvant therapy in patients who are currently receiving but are not adequately controlled on an inhaled corticosteroid. Monotherapy with a LABA without concomitant use of an inhaled corticosteroid is contraindicated in the treatment of asthma. Do not use salmeterol for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Paradoxical bronchospasm that may be life threatening may occur with use of inhaled agents; this should be distinguished from inadequate response. If paradoxical bronchospasm occurs, discontinue use and institute alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Immediate hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria, have been reported; discontinue immediately if signs/symptoms of a hypersensitivity reaction occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serious effects/fatalities: Do not exceed recommended dose or frequency or use with other medications containing LABAs; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>
<p style="text-indent:-2em;margin-left:4em;">• Upper airway symptoms: There have been reports of laryngeal spasm, irritation, swelling (stridor, choking) with use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, arrhythmia, coronary insufficiency, hypertension); beta agonists may cause elevation in blood pressure and heart rate. Beta-2 agonists may also produce changes in ECG (eg, T wave, prolongation of the QTc interval, ST segment depression).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; beta-2 agonists may increase serum glucose and aggravate ketoacidosis; the effect is usually transient.</p>
<p style="text-indent:-2em;margin-left:4em;">• Exercise-induced bronchospasm: Because LABAs may disguise poorly controlled persistent asthma, frequent or chronic use of LABAs for exercise-induced bronchospasm is discouraged by the NIH Asthma Guidelines (NIH 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; accumulation of salmeterol in plasma may occur in hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in hyperthyroidism; beta-2 agonists may stimulate thyroid activity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Use with caution in patients with hypokalemia; beta-2 agonists may decrease serum potassium; the effect is usually transient.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with seizure disorders; beta agonists may result in CNS stimulation/excitation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric:<b> [US Boxed Warning]: LABAs may increase the risk of asthma-related hospitalization in pediatric and adolescent patients. A fixed-dose combination product containing both an inhaled corticosteroid (ICS) and a LABA is preferred in pediatric patients who require addition of a LABA to an ICS to ensure adherence with both drugs. In cases where use of a separate ICS and LABA is indicated, appropriate steps must be taken to ensure adherence with both treatment components; if adherence cannot be ensured, patient should be switched to a fixed-dose combination product.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Powder for oral inhalation may contain lactose; use is contraindicated in patients with severe milk protein allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Asthma: Not indicated for the initial (rescue) treatment of acute episodes of bronchospasm. Do <b>not</b> initiate in patients with significantly worsening or acutely deteriorating asthma; reports of severe (sometimes fatal) respiratory events have been reported when salmeterol has been initiated in this situation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: COPD: Do <b>not</b> use for acute episodes of COPD. Do <b>not</b> initiate in patients with significantly worsening or acutely deteriorating COPD. Data are not available to determine if LABA use increases the risk of death in patients with COPD.</p></div>
<div class="block foc drugH1Div" id="F219849"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Serevent Diskus: 50 mcg/actuation (28 ea [DSC], 60 ea) [contains lactose]</p></div>
<div class="block geq drugH1Div" id="F219834"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F219858"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol powder</b> (Serevent Diskus Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/ACT (per each): $8.47</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868211"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Serevent Diskus: 50 mcg/actuation (1 ea) [contains lactose, milk protein]</p></div>
<div class="block admp drugH1Div" id="F52613839"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral inhalation: For oral inhalation route only. Remove from foil pouch immediately prior to first use and write the "Pouch opened" and "Use by" dates on the label on the device. The "Use by" date is 6 weeks after removal from foil pouch. After opening the Diskus, hold in a level, horizontal position and activate by sliding the lever until it clicks. Before inhaling the dose, breathe out fully; do not exhale into the Diskus device. Place inhaler in mouth, close lips around mouthpiece, and inhale quickly and deeply through the Diskus; hold breath for about 10 seconds or for as long as comfortable and exhale slowly. Do not use with a spacer device or wash mouthpiece; Diskus should be kept dry. The dose indicator tells how many doses are left. When the numbers 5 to 0 appear in red, only a few doses remain. Discard device 6 weeks after removal from foil pouch or when the dose counter reads "0" (whichever comes first).</p></div>
<div class="block adm drugH1Div" id="F219853"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral inhalation:</b> Dry power inhaler: For oral inhalation only. Remove from sealed pouch immediately prior to first use. Before inhaling the dose, breathe out fully; do not exhale into the Diskus device; activate and use only in a level, flat position. Inhale quickly and deeply through the Diskus; hold breath for about 10 seconds or for as long as comfortable and exhale slowly. Do not use with a spacer device or wash mouthpiece; Diskus should be kept dry.</p></div>
<div class="block sts drugH1Div" id="F219866"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C and 25°C (68°F and 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Protect from direct heat or sunlight. Store Diskus in the unopened foil pouch and only open when ready for use. Discard device 6 weeks after removal from foil pouch or when the dose counter reads "0" (whichever comes first).</p></div>
<div class="block meg drugH1Div" id="F7874829"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2Fucm089125.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9%2Bevs591MjKrfB30zg8bRl%2BinVkgPPvXwAzfmYAnyHDQ%3D%3D&amp;TOPIC_ID=12779" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089125.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53568779"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of asthma and prevention of bronchospasm (as concomitant therapy with an inhaled corticosteroid [ICS]) in patients with reversible obstructive airway disease, including patients with nocturnal symptoms (FDA approved in ages ≥4 years and adults); prevention of exercise-induced bronchospasm (use in combination with an ICS in patients with persistent asthma) (FDA approved in ages ≥4 years and adults); maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (including emphysema and chronic bronchitis) (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Salmeterol is <b>NOT</b> indicated for the relief of acute bronchospasm.</p></div>
<div class="block mst drugH1Div" id="F219922"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salmeterol may be confused with Salbutamol, SOLU-Medrol</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Serevent may be confused with Atrovent, Combivent, sertraline, Sinemet, Spiriva, Zoloft</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F219909"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F219843"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists (Long-Acting): May enhance the adverse/toxic effect of other Beta2-Agonists (Long-Acting).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Salmeterol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Salmeterol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Salmeterol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta2-Agonists (Long-Acting) may diminish the therapeutic effect of Methacholine.  Management: Hold long-acting beta<sub>2</sub> agonists for 36 hours before methacholine use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Salmeterol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta2-Agonists may enhance the adverse/toxic effect of Theophylline Derivatives. Specifically, sympathomimetic effects may be increased. Theophylline Derivatives may enhance the hypokalemic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May increase the serum concentration of Salmeterol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F2869570"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Maternal use of beta-2 agonists are not associated with an increased risk of fetal malformations (GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled asthma is associated with adverse events in pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low-birth-weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes) (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Salmeterol is the preferred long-acting beta-2 agonist (LABA) for the management of asthma in pregnant patients (ERS/TSANZ [Middleton 2020]). Stepping down controller treatment is not recommended during pregnancy (GINA 2023). Maternal asthma symptoms should be monitored monthly (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Beta-agonists have the potential to affect uterine contractility if administered during labor.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes associated with asthma and the medications used to treat asthma in pregnancy is ongoing. Health care providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (877-311-8972 or https://mothertobaby.org). Patients may also enroll themselves.</p></div>
<div class="block mopp drugH1Div" id="F53568781"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor asthma symptoms, FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests, blood pressure, heart rate, CNS stimulation, serum glucose, serum potassium, hypersensitivity reactions; decreased bronchodilator response (tachyphylaxis).</p></div>
<div class="block pha drugH1Div" id="F219837"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Relaxes bronchial smooth muscle by selective action on beta-2 receptors with little effect on heart rate; salmeterol acts locally in the lung.</p></div>
<div class="block phk drugH1Div" id="F219855"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Asthma: 30 to 48 minutes, COPD: 2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Asthma: 3 hours, COPD: 2 to 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Systemic: Inhalation: Undetectable to poor</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 96%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; hydroxylated via CYP3A4</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~20 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (60%); urine (25%)</p></div>
<div class="block phksp drugH1Div" id="F51159858"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: May lead to accumulation of salmeterol in plasma.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F219859"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Abrilar | Serevent</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arobid hfa | Axinat | Bexitrol | Salmate | Serevent</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Serevent | Serevent evohaler</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Sybrol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aerometrol | Kolpovent | Salmeterol | Serevent</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ping te | Qi tai | Serevent</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aeromax | Salmeterol hexal | Serevent | Soltel</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Metrovent | Salmeterol | Serevent</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Beglan | Betamican | Inaspir | Serevent | Soltel</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Neovent | Serevent | Vertine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Salment | Serevent</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Neovent | Serevent</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Azrol | Salmeter | Salvent | Serobid</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Arial | Salmetedur | Serevent</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Serevent | Zamtirel</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Salmeterol | Serevent</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Meterol | Serevent</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Serevent | Servent</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Pulveril | Serevent</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dilamax | Serevent | Ultrabeta</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Salmeter | Serevent</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Serevent | Serevent evohaler</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Serevent | Serevent N</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Serevent | Sybrol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Astmerole | Serevent</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Salmeter | Serevent</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dilatplus | Serevent</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Salmebid | Salmeter | Salspray | Serevent</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Serevent</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21444888">
<a name="21444888"></a>Anderson JL, Adams CD, Antman EM, et al, "2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," <i>Circulation</i>, 2011, 123(18):e426-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/21444888/pubmed" id="21444888" target="_blank">21444888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15256389">
<a name="15256389"></a>Bateman ED, Boushey HA, Bousquet J, et al, “Can Guideline-Defined Asthma Control Be Achieved? The Gaining Optimal Asthma Control study,” <i>Am J Respir Crit Care Med</i>, 2004, 170(8):836-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/15256389/pubmed" id="15256389" target="_blank">15256389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7884959">
<a name="7884959"></a>Bone RC, “Another Word of Caution Regarding a new Long-Acting Bronchodilator,” <i>JAMA</i>, 1995, 273(12):967-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/7884959/pubmed" id="7884959" target="_blank">7884959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1723379">
<a name="1723379"></a>Brogden RN and Faulds D, “Salmeterol Xinafoate: A Review of Its Pharmacological Properties and Therapeutic Potential in Reversible Obstructive Airways Disease,” <i>Drugs</i>, 1991, 42(5):895-912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/1723379/pubmed" id="1723379" target="_blank">1723379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8098238">
<a name="8098238"></a>Castle W, Fuller R, Hall J, et al, “Serevent Nationwide Surveillance Study: Comparison of Salmeterol With Salbutamol in Asthmatic Patients Who Require Regular Bronchodilator Treatment,” <i>BMJ</i>, 1993, 306(6884):1034-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/8098238/pubmed" id="8098238" target="_blank">8098238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8497705">
<a name="8497705"></a>Clark CE, Ferguson AD, and Siddorn JA, “Respiratory Arrests in Young Asthmatics on Salmeterol,” <i>Respir Med</i>, 1993, 87(3):227-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/8497705/pubmed" id="8497705" target="_blank">8497705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7705125">
<a name="7705125"></a>Devoy MA, Fuller RW, and Palmer JB, “Are There any Detrimental Effects of the Use of Inhaled Long-Acting Beta<sub>2</sub>-Agonists in the Treatment of Asthma?” <i>Chest</i>, 1995, 107(4):1116-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/7705125/pubmed" id="7705125" target="_blank">7705125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2">
<a name="GINA.2"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Updated 2021. Accessed December 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hatton.1">
<a name="Hatton.1"></a>Hatton MQ, Allen MB, Mellor EJ, et al, “Salmeterol Rash,” <i>Lancet</i>, 1991, 337(8750):1169-70.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7905757">
<a name="7905757"></a>Meyer JM, Wenzel CL, and Kradjan WA, “Salmeterol: A Novel, Long-Acting Beta<sub>2</sub>-Agonist,” <i>Ann Pharmacother</i>, 1993, 27(12):1478-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/7905757/pubmed" id="7905757" target="_blank">7905757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. <a href="http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" target="_blank">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16424409">
<a name="16424409"></a>Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. <i>Chest</i>. 2006;129(1):15-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/16424409/pubmed" id="16424409" target="_blank">16424409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23634861">
<a name="23634861"></a>Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. <i>Am J Respir Crit Care Med</i>. 2013;187(9):1016‐1027. doi:10.1164/rccm.201303-0437ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/23634861/pubmed" id="23634861" target="_blank">23634861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Serevent.1">
<a name="Serevent.1"></a>Serevent Diskus (salmeterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Serevent.2">
<a name="Serevent.2"></a>Serevent Diskus (salmeterol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. <a href="http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Published August 28, 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27665489">
<a name="27665489"></a>Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update-2016. <i>J Allergy Clin Immunol</i>. 2016;138(5):1292-1295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/salmeterol-pediatric-drug-information/abstract-text/27665489/pubmed" id="27665489" target="_blank">27665489</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12779 Version 209.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
